Acumen Pharmaceuticals to Participate in the Bank of America Securities 2026 Health Care Conference
Acumen Pharmaceuticals (NASDAQ: ABOS) announced management will participate in a fireside chat at the Bank of America Securities 2026 Health Care Conference on Thursday, May 14, 2026 at 8:55 a.m. PT / 11:55 a.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Acumen Pharmaceuticals (NASDAQ: ABOS) announced management will participate in a fireside chat at the Bank of America Securities 2026 Health Care Conference on Thursday, May 14, 2026 at 8:55 a.m. PT / 11:55 a.m. ET.
The session will be webcast live and archived for 90 days under the Investors tab at the company website.
Details
News Market Reaction – ABOS
On May 8, the first trading day after this news, ABOS closed 3.64% above the previous close.
Data tracked by StockTitan Argus for the May 8 session.
Key Figures
- Conference date
- May 14, 2026
- Bank of America Securities 2026 Health Care Conference fireside chat
- Session time PT
- 8:55 a.m. PT
- Scheduled start time for fireside chat
- Session time ET
- 11:55 a.m. ET
- Scheduled start time for fireside chat
- Webcast archive duration
- 90 days
- Replay availability under Investors tab on company website
Historical Context
-
Announcement of timing for Q1 2026 financial results and webcast.
-
Reported higher 2025 net loss and increased R&D spending with going concern note.
-
Set date and logistics for Q4 and year-end 2025 earnings call.
-
Presented new preclinical and biomarker data on enhanced brain delivery and antibodies.
-
Announced $35.75M private placement at $3.30 per share to fund EBD program.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
amyloid beta oligomers medical
alzheimer’s disease medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEWTON, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, announced today that management will participate in a fireside chat at the Bank of America Securities 2026 Health Care Conference on Thursday, May 14, 2026, at 8:55 a.m. PT/11:55 a.m. ET.
The live webcast may be accessed under the Investors tab on www.acumenpharm.com and will be archived for 90 days.
About Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD). Acumen’s scientific founders pioneered research on AβOs, which a growing body of evidence indicates are early and persistent triggers of Alzheimer’s disease pathology. Acumen is currently focused on advancing its lead investigational product candidate, sabirnetug (ACU193), a humanized monoclonal antibody that selectively targets toxic soluble AβOs, in its ongoing Phase 2 clinical trial ALTITUDE-AD (NCT06335173) in early symptomatic Alzheimer’s disease patients, following positive results in its Phase 1 trial INTERCEPT-AD. Acumen is also investigating a subcutaneous formulation of sabirnetug using Halozyme’s proprietary ENHANZE® drug delivery technology. Acumen is also collaborating with JCR Pharmaceuticals to develop an Enhanced Brain Delivery (EBD™) therapy for Alzheimer’s disease utilizing a transferrin-receptor-targeting blood-brain barrier-penetrating technology. The company is headquartered in Newton, Mass. For more information, visit www.acumenpharm.com.
Investors:
Alex Braun
abraun@acumenpharm.com
Media:
ICR Healthcare
AcumenPR@icrhealthcare.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.